Longitudinal changes in LIC and other parameters in patients receiving different chelation regimens: Data from LICNET

Abstract

These findings suggest as longitudinal variation in the LIC is possible, across all chelation regimens. It confirms as SF levels not always can be used for estimating changes in LIC.

Reduction of Liver Iron Load in Adult Patients with β-Thalassemia Major Treated with Modern Chelation Modalities

“…Median change in LIC and correlation with serum ferritin levels has been reported. 19 Confirmation of these important findings for a 4-year period is provided by our study in a similar population of patients. Mean T2* MRI value or mean changes in T2* MRI value after usage of iron chelators is widely reported.…”

Evaluation of safety and efficacy of Deferoxamine compared with deferasirox in transfusion dependent beta thalassemia patients: a single center retrospective study

“…Such people requires frequent blood transfusion which resulted in accumulation of iron with subsequent organ damage and death [4,5] . Patients with iron overload need iron chelation therapy for improvement with iron chelators (deferiprone, deferasirox, or deferoxamine) [6,7] . Deferoxamine (DFO), a naturally occurring trihydroxamic acid produced by Streptomyces pilosus, is an iron chelating agent administered as intramuscularly [8] , intravenously [9] or subcutaneously [10] and considered as standard therapy for iron overload worldwide in patients with transfusion dependent βthalassemia [11,12] .…”

Iron chelators or therapeutic modulators of iron overload: Are we anywhere near ideal one?

“…Di Maggio and Maggio4 evaluated 10 trials on various iron chelators singly or in combination for iron overloaded transfusion-dependent beta-thalassaemia major. Longitudinal changes in liver iron concentrations using different chelation regimens were discussed well by Vitrano et al 1. There is a need for better chelators while search for optimum chelation regimen combining different chelators continues.…”

“…Iron overload is an important cause of mortality and morbidity in chronic transfusion-dependent states commonly exemplified by transfusion-dependent beta-thalassaemia syndromes [including non-transfusion-dependent (NTD) thalassaemia intermedia] as well as transfusion-dependent myelodysplastic syndromes (MDS). Hence, therapeutic iron chelation is indicated in these conditions12345. There seems to be an increasing interest for different iron chelators and labile iron pool for patients with thalassaemia syndromes (thalassaemia major and thalassaemia intermedia) and transfusion-dependent MDS with respect to their efficacy, tolerability, safety, cost and long-term side effects.…”

“…There seems to be an increasing interest for different iron chelators and labile iron pool for patients with thalassaemia syndromes (thalassaemia major and thalassaemia intermedia) and transfusion-dependent MDS with respect to their efficacy, tolerability, safety, cost and long-term side effects. Several studies have been published recently on this topic123456789. Di Maggio and Maggio4 evaluated 10 trials on various iron chelators singly or in combination for iron overloaded transfusion-dependent beta-thalassaemia major.…”